The Factors That Affect the Infection of COVID-19

April 15, 2021 updated by: Gulbeyaz Can, Istanbul University - Cerrahpasa (IUC)

Evaluation of The Factors That Affect The Infection Of Covid-19 In Turkish Society

The number of new Coronavirus-2019 (Covid-19) cases is increasing day by day despite the warnings "Stay at home! Wear a mask! Keep social distance!". The aim of this descriptive study is to determine the risk factors that affect the Covid-19 infection in Turkey.

The online link of the form created on Google forms was sent to the participants' phones between 18.10.2020 and 18.11.2020.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Detailed Description

The number of new Coronavirus-2019 (Covid-19) cases is increasing day by day despite the warnings "Stay at home! Wear a mask! Keep social distance!". The aim of this descriptive study is to determine the risk factors that affect the Covid-19 infection in Turkey.

The majority of the lands within the Republic of Turkey cover Anatolia, while a minor part covers Thrace, the southeast extension of the Balkan Peninsula. The population of Turkey is 83,154,997. Based on the natural, human and financial characteristics, the country consists of seven regions: Mediterranean, Eastern Anatolia, Aegean, Southeastern Anatolia, Central Anatolia, Marmara, and Black Sea. The majority of the population lives in the Marmara Region. The online link of the form created on Google forms was sent to the participants' phones between 18.10.2020 and 18.11.2020 and participants' informed consent was obtained.

A 43-item questionnaire form which had two sections and was prepared by the researcher in line with the literature was used in data collection. The first section questioned participants' personal characteristics (first letters of participants' names and surnames, date of birth, profession, employment status, risk of Covid-19 infection, family type, etc.), while the second section questioned the practices of following 14 rules declared by the Turkish Ministry of Health to prevent the Covid-19 pandemic (using a mask, observing the hand hygiene and social distance, etc.) and whether participants were diagnosed with Covid-19. Identity details that could help identify the participants were not questioned.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
1104

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Istanbul, Turkey, 34854
        • Istanbul University-Cerrahpasa Florence Nightingale Nursing Faculty

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The majority of the lands within the Republic of Turkey cover Anatolia, while a minor part covers Thrace, the southeast extension of the Balkan Peninsula. The population of Turkey is 83,154,997. Based on the natural, human and financial characteristics, the country consists of seven regions: Mediterranean, Eastern Anatolia, Aegean, Southeastern Anatolia, Central Anatolia, Marmara, and Black Sea. The majority of the population lives in the Marmara Region. Many people from seven regions of Turkey were invited to participate in the study, only 1264 individuals participated. The data of 1104 people who agreed to participate and completed the assessment form thoroughly were included. Data of 160 were excluded owing to answering certain items twice.

Description

Inclusion Criteria:

  • Being over the age of 18
  • Be in good mental and mental health
  • To be able to read and write

Exclusion Criteria:

  • Being under the age of 18

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Other
  • Time Perspectives: Cross-Sectional

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Risk factors affecting the infection of Covid-19 in Turkish society
Time Frame: Last 6 month
Risk factors for Covid-19 infection
Last 6 month

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Difference between the protective measures taken from Covid-19 cases and healthy people
Time Frame: Last 6 month
Protective measures taken during the Covid-19 Pandemic
Last 6 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Istanbul University - Cerrahpasa (IUC)

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Gulbeyaz CAN, Prof., IUC Florence Nıghtingale Nursing Faculty

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
October 18, 2020

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
November 18, 2020

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 25, 2021

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
April 12, 2021

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 15, 2021

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 19, 2021

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
April 19, 2021

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 15, 2021

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
April 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • Covid-19 Infection

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings